On May 28, WuXi Biologics fell 3.15% in regular trading, trading at HK$32.58/share, with trading volume of HK$89.4 million. The decline marks the second consecutive session of losses following the stock's sharp rally on May 26, when it surged as much as 7% on the announcement of a US$400 million share buyback plan.

The initial buyback euphoria has faded amid multiple headwinds. Market participants have flagged the contradiction between the company's repurchase and major shareholder Biologics Holdings' disposal of 150 million shares at HK$38.52 per share just 11 days prior, reducing its stake below the major shareholder threshold. Additionally, the upcoming removal of CXO companies from the Hang Seng Hong Kong-listed Innovative Drug index effective June 30 is expected to trigger passive selling from tracking ETFs, with WuXi Biologics previously holding approximately 9.8% index weight.

The broader CXO sector is under pressure, with WUXI APPTEC down 3.05%, GENSCRIPT BIO down 3.23%, and WUXI XDC down 3.49%. The CSI CXO Index trades at 26.30x TTM PE, sitting at only the 16.19th percentile since inception.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)